3,421 reports of this reaction
6.9% of all CANAGLIFLOZIN reports
#1 most reported adverse reaction
DIABETIC KETOACIDOSIS is the #1 most commonly reported adverse reaction for CANAGLIFLOZIN, manufactured by Janssen Pharmaceuticals, Inc.. There are 3,421 FDA adverse event reports linking CANAGLIFLOZIN to DIABETIC KETOACIDOSIS. This represents approximately 6.9% of all 49,711 adverse event reports for this drug.
Patients taking CANAGLIFLOZIN who experience diabetic ketoacidosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIABETIC KETOACIDOSIS is moderately reported among CANAGLIFLOZIN users, representing a notable but not dominant share of adverse events.
In addition to diabetic ketoacidosis, the following adverse reactions have been reported for CANAGLIFLOZIN:
The following drugs have also been linked to diabetic ketoacidosis in FDA adverse event reports:
DIABETIC KETOACIDOSIS has been reported as an adverse event in 3,421 FDA reports for CANAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIABETIC KETOACIDOSIS accounts for approximately 6.9% of all adverse event reports for CANAGLIFLOZIN, making it one of the most commonly reported side effect.
If you experience diabetic ketoacidosis while taking CANAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.